A5082211879- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Colorectal Cancer Treatments and Studies
- Renal and related cancers
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Iron Metabolism and Disorders
- PARP inhibition in cancer therapy
- Erythropoietin and Anemia Treatment
- Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- MRI in cancer diagnosis
- COVID-19 and Mental Health
- Ear and Head Tumors
- Cardiac tumors and thrombi
- Head and Neck Surgical Oncology
- Hair Growth and Disorders
Narayana Health
2022-2025
Cancer Institute (WIA)
2020-2025
Nethradhama Superspeciality Eye Hospital
2021-2025
Rabindranath Tagore International Institute of Cardiac Sciences
2023-2025
Tata Memorial Hospital
2014-2021
Case Western Reserve University
2021
Homi Bhabha National Institute
2019
Deenanath Mangeshkar Hospital and Research Center
2016
Gauhati Medical College and Hospital
2008
King Edward VII Hospital
1945
Introduction Anemia, a frequently encountered issue among cancer patients undergoing chemotherapy, is regrettably underappreciated despite its prevalence and profound impact on their well-being. Chemotherapy-induced anemia (CIA) diminishes the quality of life, causing fatigue, breathlessness, decline in performance status. However, correcting can lead to notable improvements these parameters. Notably, darbepoetin alpha (DA) has shown efficacy addressing this context. This real-world study...
Comprehensive genomic profiling (CGP) assay is increasingly used in low-middle-income countries to detect clinically relevant alterations despite its clinical benefits not being well known. Here, we describe the proportion of patients with advanced cancer India who received targeted therapy for an actionable genetic alteration identified on CGP assays.This was a multicenter, retrospective cohort study adult nonhematologic malignancies underwent test. If ≥ 6 months, they were considered have...
PURPOSE The spectrum of EGFR is inadequately researched in patients with early-stage non–small cell lung cancer (NSCLC) India. EARLY-epidermal growth factor receptor (EGFR) India (ClinicalTrials.gov identifier: NCT04742192 ), as part a noninterventional, real-world global study, evaluated the prevalence mutations NSCLC METHODS Prospective data from adult surgically resected stage IA to IIIB (American Joint Committee on Cancer eighth edition) between March 2021 and October 2022 were analyzed....
347 Background: Immune checkpoint inhibitors, predominantly pembrolizumab and dostarlimab, have been approved in deficient mismatch repair (dMMR)/ microsatellite instability (MSI) non-colorectal cancers. There is also an emerging data to suggest significant clinical activity for low-dose ICIs (LD-ICIs) these Methods: A multi-institutional retrospective analysis Indian patients with dMMR/MSI-H advanced/metastatic carcinomas treated (irrespective of dose or schedule) between 2017 2024 was...
<ns3:p>Background First line (1L) TP-Ex-like regimen followed by 2nd-line (2L) immunotherapy represents one of the standards care in platinum-sensitive recurrent and/or metastatic squamous cell carcinoma head and neck (R/M SCCHN). We report our experience from 2 tertiary institutions India. Methods This is a retrospective analysis consecutive patients R/M SCCHN treated with 1L weekly paclitaxel, carboplatin, cetuximab (PCC) maintenance (if non-progressive) or 2L nivolumab oral metronomic...
Abstract Colorectal cancer (CRC) is one of the most common malignancies across world and fourth among men in India as per Global Cancer Observatory (GLOBOCAN) data 2020. Available suggest that approximately 30% patients present with advanced/metastatic CRC (mCRC). This publication summarizes latest evidence cognizance unique challenges faced by medical oncologists treating mCRC. A panel 38 held a meeting February 2023 reviewed available for management The concentrated on recognition mCRC...
e18058 Background: HNCs are a diverse group of malignancies characterized by genetic, epigenetic, and proteomic alterations that drive tumor progression, treatment resistance, poor outcomes. Methods: Molecular profiling 273 HNC samples was conducted using semiconductor-based next-generation sequencing (NGS) platform at Datar Cancer Genetics. A subset 106 cases underwent targeted transcriptomic analysis 20,802 genes. Additionally, PD-L1 (22C3) IHC, microsatellite instability (MSI), mutational...
Objective Antimicrotubular agents are among the most commonly used classes of chemotherapeutic agents, but risk cardiovascular adverse events (CVAEs) remains unclear. Our objective was to study CVAEs associated with antimicrotubular agents. Methods The Food and Drug Administration’s Adverse Event Reporting System in adults from 1990 2020. Reported single-agent (only taxane or vinca alkaloid) were compared combination therapy (with at least one four major cardiotoxic drugs: anthracycline,...
Cancer-associated anemia (CAA) remains a major unmet need that compromises overall survival (OS) and quality of life (QoL). Currently, available guidelines do not take into consideration the unique challenges in low- middle-income countries (LMIC). Our CAA patients have to battle preexisting impaired nutritional status, depleted body iron stores, financial limitations, difficulty having easily accessible affordable healthcare. Hence, we fulfilled for LMIC. A group subject experts were put...
The present match pair analysis was planned to compare the efficacy of cetuximab-paclitaxel-based chemotherapy versus metronomic therapy.Sixty patients with metastatic/recurrent head and neck squamous cell cancer treated weekly paclitaxel (80 mg/m2) cetuximab were matched sixty oral consisting methotrexate celecoxib. progression-free survival (PFS) overall (OS) between cohorts compared using log-rank test. Cox proportional regression model used identify independent factors affecting PFS...
<ns4:p><ns4:bold>Background:</ns4:bold> First line (1L) TP-Ex-like regimen followed by 2nd-line (2L) immunotherapy represents one of the standards care in platinum-sensitive recurrent and/or metastatic squamous cell carcinoma head and neck (R/M SCCHN). We report our experience from 2 tertiary institutions India. <ns4:bold>Methods:</ns4:bold> This is a retrospective analysis consecutive patients R/M SCCHN treated with 1L weekly paclitaxel, carboplatin, cetuximab (PCC) maintenance (if...
Pazopanib is one of the recently introduced first-line therapeutic options in treatment metastatic renal cell carcinoma (mRCC). There no published literature from India on use pazopanib mRCC.We report efficacy and toxicity analysis therapy administered for patients with mRCC at our institute. It a retrospective prospectively maintained continuous data.Between March 2013 December 2015, 28 have been treated pazopanib. The median age was 56.5 years 23 males five females. Sixty-eight percent had...
Nonclear cell (NCC) metastatic renal carcinoma (mRCC) is a biologically heterogeneous entity. We report the outcomes of NCC mRCC treated with first-line vascular endothelial growth factor (VEGF) inhibitors or mammalian target rapamycin (mTOR) at our institute. This first such from India.This retrospective analysis 40 consecutive patients between January 2013 and June 2015 in routine clinical practice The primary endpoint analyzed was overall survival (OS) respect to type treatment tumor...
Triple-negative breast cancer poses distinct challenges because it lacks hormone receptors and does not have human epidermal growth factor receptor 2 (HER2) amplification. Mutations in BRCA1/2 genes are associated with homologous recombination deficiency tumors, rendering them susceptible to poly (ADP-ribose) polymerase (PARP) inhibitors. Notably, germline mutations linked clinical features, including an increased risk of triple-negative (TNBC) a younger age onset. PARP inhibitors such as...
// Vijay Patil 1 , 7 * Amit Joshi Vanita Noronha Vivek Agarwala Anuradha Chougule Sadhana Kanan 2 Atanu Bhattacharjee 3 Arun Chandrasekharan Nikhil Pande Vijai Simha Supriya Goud Sucheta More Rajiv Kumar 4 Abhishek Mahajan 5 Janu Nilendu Purandare 6 and Prabhash Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India Biostatistics, Advanced Center for Treatment, Research, Education in Cancer, Section Centre Cancer Epidemiology, Pathology, Radiology, Nuclear Medicine, Homi...